Novartis has won the approval of the EU's drug regulating body for their Bexsero meningitis shot. The European Medicines Agency's Committee for Medicinal Products for Human Use broke the news in a statement today.
The drug will soon be cleared to start marketing the shot for use in children as early as two months in age. Industry experts say it's a big win for Novartis and could help their vaccine division:
Alistair Campbell, an analyst with Berenberg Bank in London, said it's a sigh of relief for those with a stake in the new vaccine:
"This is clearly good news. We've been waiting a long time for the approval and the delay had raised questions about the viability of the division."
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org